VEGFA and nonpapillary renal cell carcinoma: Separate external validation in a ccRCC patient cohort treated with cabozantinib found that higher LRRC75A expression was significantly associated with poorer tumor response and smaller decreases in VEGF expression, lending credence to our findings.